This company develops a breathalyzer device that detects tetrahydrocannabinol (THC) in breath samples using cavity ring-down spectroscopy. Their portable device offers immediate results for on-site drug testing, enabling organizations to maintain drug-free environments.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for detecting THC and other drugs often rely on slow, laboratory-based analysis or invasive sampling techniques like blood or urine tests. These methods can delay decision-making, are not suitable for on-site use, and may not accurately reflect recent drug use due to extended detection windows.
Solution
SpectraCann offers a portable drug breathalyzer that detects THC, opioids, and other substances in breath samples using rapid runtime cavity ring-down (rtCRD) spectroscopy. The device provides real-time results in seconds, enabling immediate on-site drug testing without the need for laboratory analysis or invasive procedures. By measuring active THC levels, the breathalyzer offers a narrow window of detection, reflecting recent cannabis consumption within 1-3 hours. The system employs AI and machine learning algorithms to enhance sensitivity and accuracy, reducing false positives and adapting to real-world data for continuous improvement.
Target Audience
SpectraCann serves employers in safety-sensitive industries such as transportation, construction, and law enforcement, as well as public safety organizations and substance abuse treatment centers.
Features
- Portable breathalyzer device for on-site drug detection
- Detects THC, opioids, and other substances using rtCRD spectroscopy
- Provides results in seconds
- Non-invasive breath sample collection
- Measures active THC to reflect recent use (1-3 hour window)
- AI and machine learning algorithms enhance sensitivity and accuracy
- Detects compounds at parts-per-trillion concentrations
- Designed to meet international standards for global compliance